Skip to main content
TVRD
NASDAQ Life Sciences

Tvardi 10-Q: $6.1M Q3 Loss, Going Concern and Material Weaknesses Disclosed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.111
Mkt Cap
$15.406M
52W Low
$0.773
52W High
$5.69
52W Position info
44% above low
Off High info
80% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

TVRD sits 44% above its 52-week low of $0.773.

Summary

Tvardi's Q3 10-Q shows a $6.1 million net loss and $22.3 million of cash, alongside a going-concern warning and material weaknesses in internal controls. The company funded the quarter largely through ATM sales and has about $7.4 million left available under its current sales agreement prospectus supplement.


Key Events · Earnings and Guidance · TVRD

  • Q3 Net Loss Widens to $6.1M

    Net loss was $6.1 million, or $(0.48) per share, versus $5.5 million, or $(0.59) per share, a year earlier. R&D rose to $4.5 million from $3.6 million on higher TTI-101 HCC trial costs.

  • Going Concern and Material Weaknesses

    The 10-Q states substantial doubt exists about the company's ability to continue as a going concern and that disclosure controls were not effective at September 30, 2026 due to material weaknesses in internal control over financial reporting.

  • Cash of $22.3M, Runway Into Q3 2027

    Cash and cash equivalents were $22.3 million at September 30, 2026, down from $30.8 million in cash, cash equivalents and short-term investments at December 31, 2025; management expects this to fund operations into Q3 2027 but says present resources will not cover at least one year without new capital.

  • ATM Funded the Quarter

    Tvardi sold 3,110,769 shares for about $11.0 million under the Original Sales Agreement Prospectus and 853,843 shares for about $2.3 million under the New Sales Agreement Prospectus Supplement in Q3, leaving about $7.4 million available.


Analysis · TVRD · Life Sciences

The Q3 10-Q confirms the $6.1 million quarterly loss and $22.3 million cash balance already reported in the same-day 8-K, but it also puts two governance red flags on the record in full: substantial doubt about the company's ability to continue as a going concern, and material weaknesses in internal control over financial reporting that leave disclosure controls not effective as of September 30, 2026. Cash of $22.3 million is down from $30.8 million in cash, cash equivalents and short-term investments at December 31, 2025, and management says present resources will not fund planned operations for at least one year without new capital. The company has been leaning on its ATM, selling 3,964,612 shares for $13.3 million gross in Q3, with only about $7.4 million left available under the current prospectus supplement. TTI-101 HCC topline data is now expected early in Q1 2027, and the TTI-109 ulcerative colitis program still needs IND clearance and additional funding.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TVRD was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.4M. The 52-week trading range was $0.77 to $5.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TVRD - Latest Insights

TVRD
Nov 13, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.11
Real-time Price: $1.12 info
Change: +$0.0094 (+0.85%) info
Market Cap: $15.406M info
TVRD
Aug 14, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.82
Real-time Price: $1.12 info
Change: -$0.700 (-38%) info
Market Cap: $15.406M info
TVRD
Aug 14, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.82
Real-time Price: $1.12 info
Change: -$0.700 (-38%) info
Market Cap: $15.406M info
TVRD
Aug 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.82
Real-time Price: $1.12 info
Change: -$0.700 (-38%) info
Market Cap: $15.406M info
TVRD
Jul 30, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.07
Real-time Price: $1.12 info
Change: -$0.950 (-46%) info
Market Cap: $15.406M info